Literature DB >> 3527396

Domperidone, a new dopamine antagonist.

M C Champion, M Hartnett, M Yen.   

Abstract

Domperidone is a dopamine antagonist that has recently been released in Canada. Unlike metoclopramide hydrochloride, the other available dopamine antagonist, it does not readily enter the central nervous system. Domperidone acts as both an antiemetic and an upper gastrointestinal tract prokinetic agent. It is rapidly absorbed after oral administration, and few side effects have been reported. Domperidone has been approved for use in Canada for the symptomatic management of upper gastrointestinal tract motility disorders and to prevent gastrointestinal symptoms associated with the use of dopamine agonist agents in Parkinson's disease. The pharmacologic features, indications and side effects of domperidone are reviewed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3527396      PMCID: PMC1491526     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  17 in total

1.  A double-blind crossover trial of domperidone in chronic postprandial dyspepsia.

Authors:  W Englert; D Schlich
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

2.  Review of the current status of prokinetic agents in gastroenterology.

Authors:  R W McCallum
Journal:  Am J Gastroenterol       Date:  1985-12       Impact factor: 10.864

3.  Bromocriptine and domperidone in the treatment of Parkinson disease.

Authors:  N Quinn; A Illas; F Lhermitte; Y Agid
Journal:  Neurology       Date:  1981-06       Impact factor: 9.910

4.  A double-blind study of domperidone in the symptomatic treatment of chronic post-prandial upper gastrointestinal distress.

Authors:  K Haarmann; F Lebkuchner; A Widmann; W Kief; M Esslinger
Journal:  Postgrad Med J       Date:  1979       Impact factor: 2.401

5.  Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease.

Authors:  Y Agid; P Pollak; A M Bonnet; J L Signoret; F Lhermitte
Journal:  Lancet       Date:  1979-03-17       Impact factor: 79.321

6.  Diabetic gastroparesis: treatment with domperidone--a double-blind, placebo-controlled trial.

Authors:  M Heer; W Müller-Duysing; I Benes; M Weitzel; M Pirovino; J Altorfer; M Schmid
Journal:  Digestion       Date:  1983       Impact factor: 3.216

Review 7.  Metoclopramide: pharmacology and clinical application.

Authors:  R Albibi; R W McCallum
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

8.  Double-blind evaluation of domperidone in acute vomiting and dyspeptic disorders.

Authors:  I Agorastos; N P Zissis; I Kaprinis; G Goulis
Journal:  J Int Med Res       Date:  1981       Impact factor: 1.671

9.  Domperidone in the treatment of dyspepsia: a double-blind placebo-controlled study.

Authors:  E Arts; H Anthoni; G de Roy; J D'Hollander; H Verhaegen
Journal:  J Int Med Res       Date:  1979       Impact factor: 1.671

Review 10.  Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

View more
  15 in total

1.  Chronic Intestinal Pseudo-obstruction.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

Review 2.  Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease.

Authors:  Lindy D Wood
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

Review 3.  Prevention and treatment of postoperative nausea and vomiting.

Authors:  A L Kovac
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

4.  Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study.

Authors:  R H Davis; M H Clench; J R Mathias
Journal:  Dig Dis Sci       Date:  1988-12       Impact factor: 3.199

5.  Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers.

Authors:  Ebony R Samuels; Ruihua H Hou; Robert W Langley; Elemer Szabadi; Christopher M Bradshaw
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

6.  Current use of domperidone and co-prescribing of medications that increase its arrhythmogenic potential among older adults: a population-based cohort study in Ontario, Canada.

Authors:  Carlos Rojas-Fernandez; Anne L Stephenson; Hadas D Fischer; Xuesong Wang; Tiago Mestre; Janine R Hutson; Margarita Pondal; Douglas S Lee; Paula A Rochon; Connie Marras
Journal:  Drugs Aging       Date:  2014-11       Impact factor: 3.923

Review 7.  Gastroesophageal reflux: clinical presentations, diagnosis and management.

Authors:  W E Waterfall; M A Craven; C J Allen
Journal:  CMAJ       Date:  1986-11-15       Impact factor: 8.262

8.  Effect of ursodeoxycholic Acid alone and ursodeoxycholic Acid plus domperidone on radiolucent gallstones and gallbladder contractility in humans.

Authors:  Ilyas Tuncer; Mustafa Harman; Yasar Colak; Ismail Arslan; M Kursad Turkdogan
Journal:  Gastroenterol Res Pract       Date:  2012-05-07       Impact factor: 2.260

9.  Effects of dopaminergic modulation on electrophysiological brain response to affective stimuli.

Authors:  Ingmar H A Franken; Ilse Nijs; Lolke Pepplinkhuizen
Journal:  Psychopharmacology (Berl)       Date:  2007-09-22       Impact factor: 4.530

10.  Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer's disease.

Authors:  Osamu Kano; Yoshihisa Urita; Hirono Ito; Takanori Takazawa; Yuji Kawase; Kiyoko Murata; Takehisa Hirayama; Ken Miura; Yuichi Ishikawa; Tetsuhito Kiyozuka; Jo Aoyagi; Yasuo Iwasaki
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-18       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.